Sentiment Trading

Niagen Bioscience Inc has expanded its flagship product, Niagen IV, to nearly 600 clinics nationwide, positioning the company for growth and increased market share in the healthy aging solutions sector.

Niagen Bioscience Inc. has expanded the availability of its Niagen IV therapy, a pharmaceutical-grade NAD+ treatment, to nearly 600 clinics across the US, marking a significant increase in its clinical footprint.

Niagen Bioscience Inc has appointed Dr. Pinchas Cohen to its Scientific Advisory Board, a move that could redefine the company’s trajectory and drive innovation in the life sciences tools and services industry.